WO2013120481A2 - Utilisation d'un agent pour la stimulation de l'expression génique de peptides antimicrobiens (amp) - Google Patents

Utilisation d'un agent pour la stimulation de l'expression génique de peptides antimicrobiens (amp) Download PDF

Info

Publication number
WO2013120481A2
WO2013120481A2 PCT/DE2013/100038 DE2013100038W WO2013120481A2 WO 2013120481 A2 WO2013120481 A2 WO 2013120481A2 DE 2013100038 W DE2013100038 W DE 2013100038W WO 2013120481 A2 WO2013120481 A2 WO 2013120481A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
purine
agent according
zinc
skin
Prior art date
Application number
PCT/DE2013/100038
Other languages
German (de)
English (en)
Other versions
WO2013120481A3 (fr
Inventor
Adolf Klenk
Christoph Abels
Michael Soerberdt
Tobias Fischer
Original Assignee
Dr. Kurt Wolff Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Kurt Wolff Gmbh & Co. Kg filed Critical Dr. Kurt Wolff Gmbh & Co. Kg
Publication of WO2013120481A2 publication Critical patent/WO2013120481A2/fr
Publication of WO2013120481A3 publication Critical patent/WO2013120481A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to the use of an agent for stimulating the gene expression of antimicrobial peptides (AMP).
  • AMP antimicrobial peptides
  • Antimicrobial preparations have long been known in pharmacy and cosmetics. They serve to eliminate a microbiological imbalance on body surfaces or in the oral cavity. Interfaces of the human organism (body) to the environment, in particular the skin with its appendages, such as the sweat or sebaceous glands, the gastrointestinal, the respiratory tract and the vaginal area are covered with numerous microorganisms, without disturbing the physiological balance. Rather, certain bacterial species are even necessary for health maintenance. Thus acidifying bacteria, e.g. Lactobacilli, by production of lactic acid lower the pH in the vagina and thus reduce the colonization with pathogenic germs.
  • biocides intervene in the cell metabolism of bacteria and prevent their colonization or reduce microbiological contamination.
  • biocides are usually exogenous substances which have a certain toxicological potential, in particular biocides Sensitizing properties are known, which have led even in younger representatives of this group of substances to a ban or a use restriction in cosmetic products.
  • lipophilic alcohols are suitable as biocides, wherein, for example, DE 10 2010 027 947 A1 describes cyclohexanol as active ingredient in antiperspirants and deodorants.
  • Caprylyl glycol in admixture with other biocides have been disclosed as a preservative system in DE 601 19 669 T2. Also elemental silver or silver ions have already been described as an active ingredient against microbiological body odor in cosmetic products.
  • One of these disclosures is called, for example, DE 10 2009 027 604 AI.
  • Probiotic active principles have also been proposed as antimicrobial protection, for example in skin treatment compositions, as disclosed in DE 10 2004 032 734 A1, or for the treatment of the gastrointestinal tract (disclosed in EP 2 277 524 A1 or GB 2 382 528 A).
  • An antimicrobial peptide is a high-molecular-weight protein that only gets its effect through a certain steric spatial organization. It may therefore be doubted that it is possible to obtain particularly complex protein structures over the entire production route from the production or recovery of the protein to the finished cosmetic or pharmaceutical agent and to keep them stable over the entire storage life of the product.
  • the invention is therefore based on the object to provide an agent which has good compatibility and stability and stimulates the body's synthesis of antimicrobial peptides.
  • the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
  • a purine or a purine alkaloid the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
  • antimicrobial peptide stimulating agent AMP
  • AMP antimicrobial peptide stimulating agent
  • Dermcidin is a so-called antimicrobial peptide, which is synthesized in large quantities in the sweat glands and has only been detected there exclusively. It protects the epithelia by activating the immune system, in particular the chemokines and cytokines, and thus from microbiological attacks from the outside.
  • the stimulation of an endogenous antimicrobial protective system may be called an ideal mode of action, which does not have the disadvantages described above; because the activation of the antimicrobial principle of action takes place via the body's own metabolic control circuits of humans.
  • High gene induction represents the first step in a metabolic cascade that eventually leads to increased synthesis of the encoded peptide dermcidin in epithelial cells.
  • the intrinsic stimulation is neither linked to the typical disadvantages of lack of compatibility nor to insufficient bioavailability, since the trigger purine or purine alkaloid for the release of dercidin has a particularly pronounced bioavailability.
  • the intrinsic stimulation of dermcine synthesis via gene activation maintains the regulatory processes that prevent overdosage and thus undesired reactions. In particular, immune reactions to exogenous peptides are avoided, which can occur in topical, inhalative or oral dermidine or AMP application.
  • DCD-1L kill pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.
  • pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.
  • the use of the agent can be enteral, intragastric, inhalative, intranasal, vaginal, (per) cutaneous or topical.
  • the agent is a cosmetic agent.
  • a hair treatment agent in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fortifiers, gels, foams or in the form of a skin treatment agent, especially skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic tonic solutions, serums, skin gels, lotions, fluids, deodorants or Antiperspirant or in the form of a treatment agent for the oral cavity, especially mouthwashes and ointments.
  • the agent is a pharmaceutical agent.
  • the agent is added to a pharmaceutical product or drug.
  • a further embodiment of the invention provides that the agent contains caffeine.
  • agent biocidal active substances selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7 1 l-trimethyl-2,6,10-dodecatrien-1-ol).
  • organohalogen compounds in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlor
  • the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.
  • the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.
  • purine and / or purine alkaloid is present as a derivative.
  • the purine and / or purine alkaloid in a concentration of 0.001 to 10,000 parts by weight, preferably in a concentration of 0.01 to 5.00 parts by weight, most preferably in a concentration of 0.1 to 2.0 wt.
  • Purines and / or purine alkaloids may be formulated together with other active ingredients and / or solvents, surfactants, emollients, vegetable, animal or synthetic lipids, fats or oils.
  • the agent according to the invention contains gel formers on an inorganic or organic basis.
  • Buffer systems with organic or inorganic acids keep the desired pH stable, preferably in the physiologically preferred range of 5-6.
  • the agent contains active substances from the group of vitamins and vitamin derivatives, light protection filters, trace elements and / or plant extracts with biologically active phytoflavones, phytohormones and / or radical scavengers.
  • antioxidants are used to stabilize purines and / or purine alkaloids and / or other active ingredients in the long term.
  • Preferred active compounds from the aforementioned fields are humectants, in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof.
  • humectants in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof.
  • Preferred monomers are 1,2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols, hexanediols such as 1,6-hexanediol Hexane triols such as 1,2,6-hexanetriol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, inositol or xylitol and mixtures of the aforementioned substances.
  • Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose, xylose, rhamnose and fucose can also be added to the composition according to the invention.
  • the proposed sugar derivatives also include mono- or dicarboxylic acids of hexoses or pentoses. Likewise, amino acids, either individually or as a mixture, can be formulated as moisturizers.
  • humectants are taurine, allantoin, (2-hydroxyethyl) urea, biosaccharides gum-1 and glycosaminoglycans and their salts and / or esters, especially hyaluronic acid, its salts and its silanol derivatives.
  • the agent of the invention cooperates with one or more humectants.
  • the humectant here is in a concentration of 0.01 to 35.00 parts by weight, preferably 1.0 to 15.0 parts by weight, most preferably in a concentration of 5.0 to 10.0 parts by weight, based on the overall recipe, before.
  • agent may contain are selected from oligomers and polymers of amino acids as well as natural betaine compounds.
  • Physiological active ingredients include vitamins, provitamins and vitamin precursors of groups A, B, C, E, H and K and their derivatives, alpha-hydroxycarboxylic acids, alpha-ketocarboxylic acids, beta-hydroxycarboxylic acids and their ester, lactone or salt form, flavonoids and flavonoid-rich plant extracts, isoflavonoids and isoflavonoid-rich plant extracts, polyphenols and polyphenol-rich plant extracts, ubiquinone and ubiquinol and their derivatives, ectoine, inorganic and organic UV filter substances, self-tanning active ingredients and skin-lightening active ingredients, and oligopeptides with alkyl or silanol side chains.
  • the agent comprises a mixture of a plurality of oligopeptides.
  • the agent poly- or oligopetides of N-acylamino acids having chain lengths of 2-26 carbon atoms.
  • Starting peptides are derived either from animal sources, in particular elastin, collagen, keratin, silk and milk protein protein hydrolysates or from preferably plant sources, such as the plant family of legumes, grasses or cereals, the kernels of apricots or almonds.
  • the agent also contains formulations with surface-active properties.
  • protein hydrolysates and their acyl derivatives which may be present in the form of fatty acid condensation products or cationic protein hydrolysates, quaternary amino acids, oligopeptides, lipopeptides or acylated amino acids or peptides.
  • Cocodimonium Hydroxypropyl Hydrolyzed Collagen Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Silk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl Silk Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl (substance names are taken from the European Inventory of Cosmetic Ingredients, (COSING)).
  • compositions are particularly suitable as additives to the composition.
  • substances that bind to keratinic materials i.
  • the horny layer of the skin or the cuticle of the hair shaft attach and improve their physical and sensory properties used.
  • the agent may contain conditioning agents. This is beneficial because the conditioners smooth the surfaces of the skin and hair, repairing damaged areas and keeping them soft and supple.
  • preferred conditioning agents are selected from fatty substances, especially vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, for example di-n-octyl ether and n-hexyl n-octyl ether, fatty acids, in particular linear and / or branched, saturated and / or unsaturated C8-30 Fatty acids, fatty alcohols, in particular saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms, ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or with 3-30, preferably 9-14 Propylene oxide units are propoxylated, ester oils,
  • the invention provides that the components added to the agent are quaternized.
  • the amount used for the Emolientien and / or care agents added to the agent in this case in a concentration of 0.1 to 50.0 wt.%, Preferably in a concentration from 0.1 to 20.0% by weight and most preferably in a concentration of 0.1-15.0% by weight, based in each case on the formulation.
  • conditioning agents included in the composition of the invention may be unstable in the presence of oxygen. Therefore, the invention provides that they are stabilized with antioxidants.
  • the antioxidants are selected from the group consisting of the amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, DL-carnosine, D-carnosine, L Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg alpha-carotene, beta-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols ( For example, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, o
  • alpha-hydroxy fatty acids phytic acid, glycosylrutin, ferulic acid, furfurylidene glucitol, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajacic acid, nordihydroguajaret Textre, trihydroxybutyrophenone).
  • Cleaning products for the skin or hair are preferably composed of a combination of anionic surfactants, amphoteric, nonionic, more rarely cationic surfactants, for example fatty alcohols of chain length C10 to C16, which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
  • anionic surfactants amphoteric, nonionic, more rarely cationic surfactants
  • fatty alcohols of chain length C10 to C16 which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
  • inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
  • These fatty acid esters are modified with polyethers.
  • Suitable anionic surfactants are, for example, lauryl ether sulfate, lauryl sulfate, myristyl sulfate, laureth sulfosuccinates, ether carboxylates with a variable degree of ethoxylation, ether sulfonates based on amino acids, sugars and fatty alcohols.
  • amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyglycosides, dodecyl polyglycosides, trilaureth 4-phosphates, di / mono sodium cocoamphoacetate, acyl / dialkylethylenediamine, for example, sodium acylampho acetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, Sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acyl amphopropionate, N-alkylamino acids such as aminopropylalkylglutamide, alkylamino-propionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyg
  • the anionic surfactants are preferably used in salt form.
  • Suitable cations are alkali metal and alkaline earth metal ions, in particular sodium, potassium and magnesium.
  • Nonionic surfactants are, for example, sarcosinates, e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10 to 20 ethylene oxide or propylene oxide units.
  • sarcosinates e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10
  • Cationic surfactants are primarily the already described as conditioning components quaternized N compounds from the group of amino acids, amino sugars or peptides.
  • gel formers are contained in the means for optimizing the flow behavior.
  • Gelling agents are, for example, organic thickeners, such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
  • organic thickeners such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
  • Hydroxypropylmethylcellulose or inorganic thickening agents such as aluminum silicates, such as organically modified or unmodified hectorites, bentonites, or the like, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • aluminum silicates such as organically modified or unmodified hectorites, bentonites, or the like
  • a mixture of polyethylene glycol and polyethylene glycol stearate or distearate such as a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • biopolymers such as chitin or chitin derivatives or poly-glucuronic or polygalacturonic acids and their amides are suitable.
  • Another group of particularly effective gels consists of modified polymers of acrylic acid.
  • the thickener is contained in the gel in a concentration of 0.1 to 30.0 parts by weight, preferably in a concentration of 0.5 to 15.0 parts by weight.
  • Prescriptions for the skin and hair care mainly consist of oils and care substances, which have to be stabilized in aqueous systems by means of emulsifiers.
  • the invention provides that the agent contains emulsifiers.
  • Suitable emulsifiers are, for example, PEG-n hydrogenated castor oil, PEG-n caprylic acid / capric acid glycerides, glyceryl oleate mixed with propylene glycol, PEG-n-stearate, ceteth-n, ceteth-n, polysorbate n, glyceryl stearate in admixture with PEG-n, glyceryl myristate, Glyceryl laurate, PEG-n-sorbitan peroleate, laureth-n, ceteareth-n, isostearyl glyceryl ether, cetylstearyl alcohol in admixture with sodium cetyl stearyl sulfate, lameth-n, steareth-n, glyceryl stearate in admixture with PEG-n stearate.
  • PEG-n-stearate glycol distearate, PEG-n-dodecyl glycol, polyglyceryl-n-PEG-n-stearate, ceteareth-n, methyl glucose sesquistearate, steareth-n, PEG-n-stearate, steareth-n in admixture with PEG-n Distearate, steareth-n, steareth-n, isosteareth-n, PEG-n dodecyglycol copolymer, methoxy-PEG-n dodecyl glycol copolymer, PEG-n sorbitan peroleate, PEG-n sorbitan perisostearate, PEG-n-glyceryl stearate, PEG- n-glyceryl stearate, PEG-n beeswax, polyglyceryl n-laurate, isostearyl diglyceryl succinate, stearamidoprop
  • the agent according to the invention can be best distributed on the surface of skin or hair, gastrointestinal or respiratory tract or vaginal area with the abovementioned active ingredient combinations, a specific galenic formulation is necessary. This depends on the individual needs of the user.
  • the agent according to the invention for dermatological applications in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-oil-in-water emulsion, macroemulsion, microemulsion, PIT emulsion, nanoemulsion, hydrodispersion, hydrogel, lipogel, mono- or multiphase solution, foam, aqueous-alcoholic solution or surfactant formulation is present.
  • the agent with applicators such as dosing tips or spray dosing in the form of aqueous, aqueous-alcoholic solutions, lotions or gels is administered.
  • agent according to the invention is used for sprays, roll-ons and deodorants.
  • alcoholic lotions, hair creams or scalp waters for example, soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided.
  • soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided.
  • the following formulation examples are intended to illustrate the subject matter of the invention without limiting it thereto. All data are in parts by weight based on the total composition. The substance names are taken from the binding inventory of cosmetic ingredients, COSING.
  • Anti-dandruff shampoo (in% by weight)

Abstract

La présente invention concerne un agent qui est bien toléré et présente une bonne stabilité, ainsi qu'un effet antimicrobien. A cet effet, ledit agent est une purine ou un alcaloïde de purine, ce dernier étant choisi dans le groupe constitué par la xanthine, la théobromine, la paraxanthine, la théophylline, la 3-isobutyl-1-méthylxanthine (IBMX) et la 1-méthylxanthine.
PCT/DE2013/100038 2012-02-13 2013-02-05 Utilisation d'un agent pour la stimulation de l'expression génique de peptides antimicrobiens (amp) WO2013120481A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012002592A DE102012002592A1 (de) 2012-02-13 2012-02-13 Verwendung eines Mittels zur Stimulation der Gen-Expression antimikrobieller Peptide (AMP)
DE102012002592.0 2012-02-13

Publications (2)

Publication Number Publication Date
WO2013120481A2 true WO2013120481A2 (fr) 2013-08-22
WO2013120481A3 WO2013120481A3 (fr) 2014-09-18

Family

ID=47842985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2013/100038 WO2013120481A2 (fr) 2012-02-13 2013-02-05 Utilisation d'un agent pour la stimulation de l'expression génique de peptides antimicrobiens (amp)

Country Status (2)

Country Link
DE (1) DE102012002592A1 (fr)
WO (1) WO2013120481A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120850A1 (fr) * 2012-12-14 2017-01-25 Unilever N.V. Niacinamide pour induire la production de peptides antimicrobiens
WO2017173236A1 (fr) * 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition désinfectante de stimulation de peptides antimicrobiens
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2022217000A1 (fr) * 2021-04-07 2022-10-13 Ingenious Ingredients, LP Composition bioactive à base de 1-méthylxanthine et son procédé d'utilisation
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6446065B2 (ja) * 2014-05-12 2018-12-26 ユニリーバー・ナームローゼ・ベンノートシヤープ 抗微生物ペプチドの生成を誘導するためのナイアシンアミド

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2382528A (en) 2001-11-12 2003-06-04 Mars Inc Consumable composition for the development of a healthy gastrointestinal tract
DE102004032734A1 (de) 2004-03-18 2005-10-06 Henkel Kgaa Präbiotisch wirksame Substanzen für Deodorantien
DE102005014687A1 (de) 2005-03-29 2006-10-12 Henkel Kgaa Zusammensetzung enthaltend ß-Defensin 2
DE60119669T2 (de) 2000-11-16 2007-05-16 Johnson & Johnson Consumer France Sas Caprylylglykol und Iodopropynylbutylcarbamat enthaltende Zusammensetzungen
DE102009027604A1 (de) 2009-07-10 2011-01-20 Henkel Ag & Co. Kgaa Kosmetische Zusammensetzungen mit Suspensionen von Silbersalzen
EP2277524A1 (fr) 2005-09-28 2011-01-26 Nordisk Rebalance A/S Traitement des maladies intestinales inflammatoires et du syndrome du côlon irritable par l'utilisation en tant qu'effecteurs thérapeutiques, de bactéries probiotiques et de céréales fermentées
DE102010027947A1 (de) 2010-04-20 2011-10-20 Henkel Ag & Co. Kgaa Hautschonende Deodorantien und Antitranspirantien

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533333A (en) * 2004-02-17 2005-10-16 Otsuka Pharma Co Ltd Human beta-defensin production accelerator
JP2010270030A (ja) * 2009-05-20 2010-12-02 Fukuoka Univ 抗菌ペプチドの発現誘導剤または分泌促進剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60119669T2 (de) 2000-11-16 2007-05-16 Johnson & Johnson Consumer France Sas Caprylylglykol und Iodopropynylbutylcarbamat enthaltende Zusammensetzungen
GB2382528A (en) 2001-11-12 2003-06-04 Mars Inc Consumable composition for the development of a healthy gastrointestinal tract
DE102004032734A1 (de) 2004-03-18 2005-10-06 Henkel Kgaa Präbiotisch wirksame Substanzen für Deodorantien
DE102005014687A1 (de) 2005-03-29 2006-10-12 Henkel Kgaa Zusammensetzung enthaltend ß-Defensin 2
EP2277524A1 (fr) 2005-09-28 2011-01-26 Nordisk Rebalance A/S Traitement des maladies intestinales inflammatoires et du syndrome du côlon irritable par l'utilisation en tant qu'effecteurs thérapeutiques, de bactéries probiotiques et de céréales fermentées
DE102009027604A1 (de) 2009-07-10 2011-01-20 Henkel Ag & Co. Kgaa Kosmetische Zusammensetzungen mit Suspensionen von Silbersalzen
DE102010027947A1 (de) 2010-04-20 2011-10-20 Henkel Ag & Co. Kgaa Hautschonende Deodorantien und Antitranspirantien

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120850A1 (fr) * 2012-12-14 2017-01-25 Unilever N.V. Niacinamide pour induire la production de peptides antimicrobiens
WO2017173236A1 (fr) * 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition désinfectante de stimulation de peptides antimicrobiens
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2022217000A1 (fr) * 2021-04-07 2022-10-13 Ingenious Ingredients, LP Composition bioactive à base de 1-méthylxanthine et son procédé d'utilisation

Also Published As

Publication number Publication date
WO2013120481A3 (fr) 2014-09-18
DE102012002592A1 (de) 2013-08-14

Similar Documents

Publication Publication Date Title
EP2174648B1 (fr) Compositions de soins pour la peau et leurs utilisations
ES2243901T3 (es) Derivados de acido ascorbico estabilizados.
WO2013120481A2 (fr) Utilisation d&#39;un agent pour la stimulation de l&#39;expression génique de peptides antimicrobiens (amp)
JPWO2004016236A1 (ja) 化粧料
EP3436158B1 (fr) Compositions topiques contenant les extraits de plantes
KR101015702B1 (ko) 해조추출물을 포함하는 염증 및 피부자극 개선 및 완화용조성물
DE102006060439A1 (de) Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
US10137070B2 (en) Composition including ionone or salt thereof as active ingredient and having effect of enhancing skin moisturizing, exfoliating skin, improving skin elasticity, inhibiting erythema, improving skin wrinkles, or alleviating skin photoaging
KR100947638B1 (ko) 용암해수염을 함유하는 조성물
JP6505905B2 (ja) カテキン脂肪酸誘導体の化粧料
US20210361559A1 (en) Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis
EP2633885A1 (fr) Liaisons et mélanges destinés à influencer les états inflammatoires
DE19634019A1 (de) Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
KR20200043406A (ko) 미백제, 미백용 피부 외용제 및 피부의 미백 방법
EP1539128B1 (fr) Utilisation de substances pour proteger la peau
WO2018196993A1 (fr) Concentré de jus pressé de plante fraîche d&#39;achillée, production et utilisation
EP1094787A1 (fr) Preparations pour proteger la peau de jeunes enfants contre la dermatitis ammoniacalis
KR102626479B1 (ko) 겐티오피크로시드 부재 겐티아나 추출물
EP2090296B1 (fr) Utilisation de complexes de matière active à base de panthénol, glycérine, citrate et/ou bisabolol contre les allergies au pollen
KR20160061601A (ko) 모로헤이야, 은행잎 및 클로렐라 추출물을 유효성분으로 함유하는 화장료 조성물 및 약학조성물
JP2020189816A (ja) ビタミンｃ誘導体組成物
KR20210036166A (ko) 피부장벽 강화용 조성물
KR102408170B1 (ko) 아이소프로컬큐메놀을 함유하는 항노화 또는 피부재생용 조성물
KR102408169B1 (ko) 오카닌을 함유하는 항노화 또는 피부재생용 조성물
JP5137786B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有クレンジング化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13708072

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13708072

Country of ref document: EP

Kind code of ref document: A2